Department of Radiation Oncology,Tianjin Medical University Cancer Institute& Hospital,Key Laboratory of Cancer Prevention and Therapy,National Clinical Research Center for Cancer,Tianjin 300060,China
Abstract Objective To evaluate the correlation of different fractionation schedules in radiotherapy with the local control (LC) and overall survival (OS) rates in patients with extensive-stage small cell lung cancer (ES-SCLC), and to figure out the relationship between different fractionation schedules in radiotherapy and the prognosis of ES-SCLC. Methods One hundred and ten patients newly diagnosed with ES-SCLC from February 2010 to March 2015 received chemoradiotherapy. According to the radiation dose, all patients were divided into hypo-fractionation group (30-45 Gy/3 Gy/10-15 f, n=31) and conventional fractionation group (54-60 Gy/1.8-2.0 Gy/27-30 f, n=79). In all patients, 90.9% had stage Ⅳ SCLC;21 patients had brain metastasis;39 patients were treated with prophylactic cranial irradiation (PCI). The Kaplan-Meier method was used to calculate the survival time and log-rank test was used for between-group comparison. Between-group comparison of categorical data was made by χ2 test. Results The number of patients followed-up were 85 at 2-years. In all patients, the 2-year OS, progression-free survival (PFS), and LC rates were 27.7%, 17.5%, and 38.9%, respectively. The hypo-fractionation group had similar prognosis to the conventional fractionation group. There were no significant differences in the 2-year OS, PFS, and LC rates between the two groups (35% vs. 26%, P=0.886;18% vs. 16%, P=0.560;67% vs. 36%, P=0.159). There was also no significant difference in the 2-year OS rate between patients treated with and without PCI (44% vs. 18%, P=0.044). In 84 patients with treatment failure, 11 had local recurrence, 41 had distant metastasis, and 32 had local recurrence plus distant metastasis. Conclusions The hypofractionated radiotherapy has similar efficacy but substantially shortened radiation time compared with conventionally fractionated radiotherapy. The palliative hypofractionated radiotherapy requires further study for ES-SCLC.
Xu Liming,Zhao Lujun,Chen Xiuli et al. Comparison of efficacy of different fractionation schedules in radiotherapy for extensive-stage small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2015, 24(5): 488-492.
Xu Liming,Zhao Lujun,Chen Xiuli et al. Comparison of efficacy of different fractionation schedules in radiotherapy for extensive-stage small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2015, 24(5): 488-492.
[1] Govindan R,Page N,Morgensztern D,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J].J Clin Oncol,2006,24(28):4539-4544.DOI:10.1200/JCO.2005.04.4859. [2] Riess JW,Lara PNJr..Left behind? Drug discovery in extensive-stage small-cell lung cancer[J].Clin Lung Cancer,2014,15(2):93-95.DOI:10.1016/j.cllc.2013.12.010. [3] Lally BE,Urbanic JJ,Blackstock AW,et al. Small cell lung cancer:have we made any progress over the last 25 years?[J].Oncologist,2007,12(9):1096-1104.DOI:10.1634/theoncologist.12-9-1096. [4] O′Brien MER,Ciuleanu TE,Tsekov H,et al. Phase Ⅲ trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer[J].J Clin Oncol,2006,24(34):5441-5447.DOI:10.1200/JCO.2006.06.5821. [5] Kubota K,Hida T,Ishikura S,et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202):a randomised phase 3 study[J].Lancet Oncol,2014,15(1):106-113.DOI:10.1016/S1470-2045(13)70511-4. [6] Xenidis N,Kotsakis A,Kalykaki A,et al. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer:a multicenter phase Ⅱ study[J].Lung Cancer,2010,68(3):450-454.DOI:10.1016/j.lungcan.2009.08.012. [7] Giuliani ME,Atallah S,Sun A,et al. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy[J].Clin Lung Cancer,2011,12(6):375-379.DOI:10.1016/j.cllc.2011.03.028. [8] Jeremic B,Shibamoto Y,Nikolic N,et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer:a randomized study[J].J Clin Oncol,1999,17(7):2092-2099. [9] Zhu H,Zhou ZM,Wang Y,et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis[J].Cancer,2011,117(23):5423-5431.DOI:10.1002/cncr.26206. [10] Yee D,Butts C,Reiman A,et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer[J].Radiother Oncol,2012,102(2):234-238.DOI:10.1016/j.radonc.2011.08.042. [11] Slotman BJ,Van Tinteren H,Praag JO,et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer:a phase 3 randomised controlled trial[J].Lancet,2015,385(9962):36-42.DOI:10.1016/S0140-6736(14)61085-0. [12] Cox JD,Stetz J,Pajak TF.Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)[J].Int J Radiat Oncol Biol Phys,1995,31(5):1341-1346.DOI:10.1016/0360-3016(95)00060-C. [13] Eisenhauer EA,Therasse P,Bogaerts J,et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.DOI:10.1016/j.ejca.2008.10.026. [14] Chute JP,Chen T,Feigal E,et al. Twenty years of phase Ⅲ trials for patients with extensive-stage small-cell lung cancer:perceptible progress[J].J Clin Oncol,1999,17(6):1794-1801. [15] Schiller JH,Adak S,Cella D,et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer:E7593-a phase Ⅲ trial of the Eastern Cooperative Oncology Group[J].J Clin Oncol,2001,19(8):2114-2122. [16] Hanna N,Bunn PAJr., Langer C,et al. Randomized phase Ⅲ trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer[J].J Clin Oncol,2006,24(13):2038-2043.DOI:10.1200/JCO.2005.04.8595. [17] Ou SH,Ziogas A,Zell JA.Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC):the importance of smoking history,socioeconomic and marital statuses,and ethnicity[J].J Thorac Oncol,2009,4(1):37-43.DOI:10.1097/JTO.0b013e31819140fb. [18] Schild SE,Bonner JA,Hillman S,et al. Results of a phase Ⅱ study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53)[J].J Clin Oncol,2007,25(21):3124-3129.DOI:10.1200/JCO.2006.09.9606. [19] Schild SE,Foster NR,Meyers JP,et al. Prophylactic cranial irradiation in small-cell lung cancer:findings from a north central cancer treatment group pooled analysis[J].Ann Oncol,2012,23(11):2919-2924.DOI:10.1093/annonc/mds123
2015, Vol. 24 
